Shire Buys Premacure for Blindness-Preventing Drug in Infants

Shire Plc (SHP), a maker of drugs for rare genetic diseases, bought Sweden’s Premacure AB to gain an experimental treatment against a blindness-causing disorder in babies born prematurely.

Shire will pay an upfront fee for the closely held company, which is based in Uppsala, and further payments if the drug meets certain development targets, the Dublin-based company said in a statement today, without disclosing amounts. The initial payment is probably less than $30 million, said Savvas Neophytou, an analyst at Panmure Gordon & Co.

The acquisition gives Shire a protein-replacement therapy called insulin-like growth factor 1, or IGF-1, against retinopathy of prematurity, one of the most common causes of vision loss in childhood. The deal is Shire’s second this year, and fits with a strategy of building its rare disease business, analysts including Mark Clark at Deutsche Bank AG said.

Incoming Shire Chief Executive Officer Flemming Ornskov was a “fan of eye products” while at Bayer AG (BAYN) and the acquisition is “an interesting first deal following his arrival,” said Navid Malik, an analyst at Cenkos Securities Plc. (CNKS)

Shire rose 0.4 percent to 2,045 pence as of 1:09 p.m. in London, giving the company a market value of 11.4 billion pounds ($17 billion).

Retinopathy of prematurity affects as many as 16,000 preterm infants in the U.S. each year, requires medical treatment in as many as 1,500 cases, and causes blindness among as many as 600 babies, Shire said.

Babies born prematurely can lack IGF-1 and the ability of fully-grown fetuses to produce it themselves. Premacure’s drug, which it’s been developing under the brand name Premiplex, is designed to replace the protein and prevent vision loss. It’s in the second of three stages of clinical trials usually needed for regulatory approval in the U.S.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.